Dara compound named an orphan drug for myeloma

Shares of pico cap Dara Biosciences (DARA +21%) jump on a massive 16x spike in volume in response the FDA's designation of KRN5500 as an Orphan Drug for the treatment of multiple myeloma. The compound is a non-narcotic non-opioid spicamycin derivative in development for chronic chemotherapy-induced peripheral neuropathy, an indication for which it was designated an Orphan Drug earlier this year. The FDA designated it a Fast Track program in 2011.

The company's market cap is only $12M. As with all investments, retail investors should do thorough due diligence here before considering deploying capital.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs